TAPBP is essential for effective CD8+ T cell responses to tumors and anti-cancer immune surveillance, as the presentation of major histocompatibility complex class-I antigens on cancer cells triggers the recognition and destruction of cancer cells by cytotoxic T cells (CTLs) (41). The gene discussed is CD8A; the disease is cancer.